11月14日至11月16日，中国疫苗行业协会（CAV）首届学术大会在福建厦门召开。万泰疫苗深度参与此 次盛会，重点展示了包括最新上市的国产九价HPV疫苗，并全面呈现了公司在疫苗研发与全球化合作方 面的坚实步伐。 在大会的权威学术分享环节，厦门大学公共卫生学院院长张军以"国产九价HPV疫苗的有效性研究"为题 发表专题报告，系统梳理了我国HPV疫苗从二价到九价的技术发展路径，并重点解读了馨可宁®9的临 床试验成果，临床数据显示馨可宁®9不仅在免疫原性与安全性上与进口同类产品相当，更在关键型别 的保护效果上表现优异。该疫苗的上市，标志着我国在高价次HPV疫苗研发与产业化方面实现重要突 破，为全球宫颈癌防控提供了高质量的中国方案。 目前，馨可宁®9已在河南、山西、内蒙古、浙江、江西、河北、天津等地区陆续启动预约，目前累计 已进入24个省，后续更多地区将逐步开放接种。同时，万泰疫苗正积极推进馨可宁®9的世界卫生组织 （WHO）预认证（PQ）工作，进一步践行为全球提供高质量疫苗，守护人类健康的承诺。 除备受瞩目的馨可宁®9（九价HPV疫苗），万泰还展示了馨可宁®（WHO预认证的双价HPV疫苗）和 益可宁®（重组戊型肝炎疫 ...

Core Insights - The first academic conference of the China Vaccine Industry Association (CAV) was held in Xiamen, Fujian, from November 14 to 16, showcasing advancements in vaccine research and development [1] - Wantai Biological Pharmacy presented its newly launched domestic nine-valent HPV vaccine, Xinkening®9, highlighting its effectiveness and safety compared to imported products [1][2] - The conference featured a report by Zhang Jun, Dean of the School of Public Health at Xiamen University, discussing the technological development of HPV vaccines in China and the clinical trial results of Xinkening®9 [1][2] Summary by Sections Conference Overview - The conference gathered experts from various sectors, including CDCs, research institutions, universities, and vaccine manufacturers, to discuss advancements in the vaccine industry [1] - Wantai Biological showcased its commitment to vaccine R&D and global collaboration [1] Xinkening®9 Vaccine - Xinkening®9 is the first domestic and second global nine-valent HPV vaccine, with clinical data published in prestigious journals [2] - The vaccine demonstrated 100% efficacy against HPV types not covered by the previous two-valent vaccine, with good safety profiles observed during trials [2] - Vaccination appointments for Xinkening®9 have started in multiple provinces, with plans for further expansion [2] Other Products and Future Plans - Wantai Biological also presented its two-valent HPV vaccine, Xinkening®, and the recombinant hepatitis E vaccine, Yikening®, which have shown effective real-world performance [3] - The company aims to continue driving innovation and high-quality development in the vaccine industry, emphasizing collaboration across government, industry, academia, and research [3]

Group 1 - The first domestically produced nine-valent HPV vaccine "Xinkening®9" has been approved for market release, priced at 499 yuan per dose, approximately 40% of the price of imported nine-valent HPV vaccines [2] - The vaccine was developed by a team led by Academician Xia Ning Shao from Xiamen University in collaboration with Wantai Biological Pharmacy, utilizing a novel prokaryotic expression system [2][3] - The development process took 18 years, involving over 20 PhD and 150 master's degree holders from Wantai Biological, marking a significant breakthrough in China's biopharmaceutical sector [2][3] Group 2 - Clinical trial results published in The Lancet Infectious Diseases indicate that "Xinkening®9" shows similar immune response and safety profiles compared to imported vaccines [3] - The vaccine effectively prevents persistent infections from seven high-risk HPV types associated with cervical cancer, establishing a protective barrier for women aged 18-45 [3] - The World Health Organization has initiated a global strategy to accelerate the elimination of cervical cancer, with China also launching an action plan that includes promoting HPV vaccination as a key objective [3] Group 3 - Wantai Biological has invested approximately 1 billion yuan in the research and development of the nine-valent HPV vaccine, with the approval of its market license expected to enhance the company's product line and core competitiveness [4] - The introduction of the domestically produced vaccine is anticipated to increase vaccination rates among eligible women, contributing to the establishment of a national immunity barrier against cervical cancer [4][5] - The affordable pricing of the vaccine is expected to benefit over 100 million women in China and positively impact global efforts to combat cervical cancer [5]